IPP Bureau
Amgen settles with FTC over US$28 billion deal
By IPP Bureau - September 04, 2023
Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products
Shilpa Medicare receives UK MHRA approval for mouth-dissolving strips to treat illnesses
By IPP Bureau - September 03, 2023
This approval has come from the company's finished dosage form manufacturing facility
Zydus receives final USFDA approval for Erythromycin Tablets
By IPP Bureau - September 03, 2023
Erythromycin tablets is used to prevent and treat infections in many different parts of the body
BioNTech to lead $2 billion mRNA-based oncology therapy market despite challenges, says GlobalData
By IPP Bureau - September 03, 2023
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Loop's health assurance model drives 200% YoY premium surge across 1000 companies
By IPP Bureau - September 02, 2023
Health Assurance is a unique healthcare model that combines health insurance with preventive healthcare with a focus on keeping people healthy while providing sick care for them when needed
India's digital startup ecosystem a catalyst for global healthcare transformation: Piyush Goyal
By IPP Bureau - September 02, 2023
Robots make it to the healthcare conference panel, reflecting the future potential of technology
USFDA delegation visits Amneal Pharmaceutical facility in Matoda
By IPP Bureau - September 02, 2023
Amneal’s site in Matoda is one of the company’s 12 pharmaceutical manufacturing facilities
Jupiter Life Line Hospitals’ IPO to open on Sept. 6
By IPP Bureau - September 02, 2023
Sets price band at ?695 to ?735 per Equity Share
Global health challenges can be resolved using digital technology: Dr Alain Labrique
By IPP Bureau - September 02, 2023
Biocon acquires oral solid dosage manufacturing facility of Eywa Pharma for US$7.7 million
By IPP Bureau - September 02, 2023
The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year
Shilpa Pharma Lifesciences’ Unit II, Raichur, Karnataka clears PMDA Japan, GMP inspection
By IPP Bureau - September 02, 2023
The inspection has concluded successfully on 1st September 2023 without any critical/major observation
Sanofi, Meningitis Research Foundation and CoMO launch awareness initiative on meningitis
By IPP Bureau - September 01, 2023
Meningitis still affects more than 2.5 million people globally each year
Sanofi announces changes to its Executive Committee
By IPP Bureau - September 01, 2023
Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.
USFDA approves BMS’ Reblozyl as first-line treatment of anemia in adults with Myelodysplastic Syndromes
By IPP Bureau - September 01, 2023
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
